Work packages

WP1   WP2   WP3   WP4   WP5  WP6

 

WP1: Activity standards for QI

(Participating partners: CEA, BEV-PTP, CMI, ENEA, NPL, OPBG)

This work package is focused on standardization of activity of radionuclides for QI. The work package leader is Christophe Bobin (CEA).

Task 1.1  Improve accuracy and traceability in QI by providing improved nuclear data for the therapeutic radionuclides 90Y and 166Ho. The objective is to halve the uncertainties in the branching ratios and emission probabilities to 1.5 % for these radionuclides.

Task 1.2  Develop a range of sealed, long-lived radioactive test sources and surrogate radioactive test sources. The radioactive test sources will be used for the QI comparison exercise in Task 2.4 and in the quasi-realistic anthropomorphic 3D phantoms in Task 2.3. They will also be used in developing the protocol for commissioning and QC for SPECT/CT and PET/CT systems in Task 2.2.

Task 1.3  Develop a new transfer instrument in order to reduce measurement uncertainties for high-energy beta-emitters such as 90Y (i.e. the aim is to reduce the uncertainty from 15 % to 2 %), which can be used as an alternative to radionuclide calibrators used for the measurement of activity in clinics.

 

WP2: Image-based quantification of 3D activity distributions

(Participating partners: UKW, BEV-PTP, CMI, ENEA, NPL, ASMN, Christie, LUND, THG, AUSL, CARD, OUHT, PSOM, RSCH, CEA, BRFAA)

This workpackage is focused on determination of 3D activity distributions from various imaging modalities. The work package leader is Michael Lassmann (UKW).

Task 2.1  Develop an expanded calibration protocol (from JRP HLT11 MetroMRT) for other MRT radionuclides, i.e. 131I and 90Y.

Task 2.2  Using the expanded calibration protocol from Task 2.1, develop a protocol for commissioning and QC for SPECT/CT and PET/CT systems.

Task 2.3  Develop 3D printing methods to generate a range of quasi-realistic anthropomorphic phantoms containing compartments fillable with known activities of radioactive liquid or standardised sealed radioactive test sources.

Task 2.4  Use the protocols from Tasks 2.1 and 2.2 to perform a QI comparison exercise amongst external and unfunded clinical project partners (and collaborators) using and the radioactive test sources from Task 1.2 and the quasi-realistic anthropomorphic 3D phantoms from Task 2.3. A method will also be defined for determining the optimal volume of interest (VOI) in the dosimetry process.

 

WP3: Computer modelling of time-variable activity distributions in multimodal imaging

(Participating partners: SCK•CEN, CMI, NPL, Christie, INSERM, LUND, THG, UKW, CARD, OUHT, RSCH)

This workpackage is focused on computer modelling and development of web-based database of reference images. The work package leader is Lara Struelens (SCK•CEN).

Task 3.1  Benchmark and further develop existing simulation tools for SPECT imaging and then link them to the quasi-realistic anthropomorphic 3D phantoms developed in Task 2.3.

Task 3.2  Develop a method for using CT imaging to determine 3D maps of density and attenuation coefficients in the body.

Task 3.3  Develop reference values of the absorbed dose for the quasi-realistic anthropomorphic 3D phantoms developed in Task 2.3.

Task 3.4  Generate modelled data for QA of the determination of non-imaging‑based dosimetry methods.

Task 3.5  Develop modelling methods for the determination of the optimal times for when to perform patient scans or whole-body measurements.

Task 3.6  Study the effects of absorbed dose uncertainty on NTCP.

Task 3.7  Design and host a web-based database of reference images to be used as reference data for commissioning and QC of QI using SPECT-CT or PET-CT.

 

WP4: Accuracy and traceability of dose calculations

(Participating partners: Christie, BEV-PTP, ENEA, NPL, ASMN, INSERM, LUND, THG, UKW, OUHT, RSCH, CARD, BRFAA)

This workpackage is focused on the determination of absorbed dose. The work package leader is Jill Tipping (Christie).

Task 4.1  Investigate different imaging and non-imaging methods of measuring activity within a patient and to determine the best methods for obtaining cumulated activity from a time-activity-curve.

Task 4.2  Perform measurements of absorbed dose for heterogeneously distributed MRT radionuclides using magnetic resonance sensitive gel and film based dosimetry.

Task 4.3  Continue development of the NPL prototype primary standard of absorbed dose to water from a radionuclide solution (from JRP HLT11 MetroMRT). This will be done in order to determine their traceability to calculations of the energy deposition from nuclear data.

Task 4.4  Provide the first comprehensive comparison of dose calculations, for a range of commercial and non-commercial dosimetry calculation platforms. The comparison will be used to identify procedures suitable for a protocol that can be used for commissioning a MRT dosimetry calculation platform.

 

WP5: Creating Impact

(Participating partners: NPL, All partners)

The aim of this work package is to facilitate the take-up of the technology and measurement infrastructure developed by the project by healthcare professionals (clinical centres) and industry (camera manufacturers, software developers, and radiopharmaceutical companies). The work package leader is Vere Smyth (NPL).

Task 5.1  Knowledge Transfer
Task 5.2  Training
Task 5.3  Uptake and Exploitation

 

WP6: Management and coordination

(Participating partners: NPL, All partners)

This work package is dedicated to the coordination of the project. The work package leader is Andrew Robinson (NPL).

Task 6.1  Project management
Task 6.2  Project meetings
Task 6.3  Project reporting